deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 3-arm NCT01892722

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase

Sponsor: Novartis Pharmaceuticals

Conditions Multiple Sclerosis
Interventions Fingolimod Interferon beta-1a Placebo capsule Placebo i.m. injection
Updated 35 times since 2017 Last updated: Nov 13, 2025 Started: Jul 26, 2013 Primary completion: Jul 14, 2017 Completion: Feb 18, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Multiple Sclerosis, this trial is ongoing. The trial is conducted by Novartis Pharmaceuticals and has accumulated 35 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~May 2018 · 8 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Mar 2019 · 5 months · monthly snapshot~Mar 2019 – ~Sep 2020 · 18 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Mar 2022 · 3 months · monthly snapshot~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Feb 2023 · 3 months · monthly snapshot~Feb 2023 – ~Sep 2023 · 7 months · monthly snapshot~Sep 2023 – ~Nov 2023 · 2 months · monthly snapshot~Nov 2023 – ~Apr 2024 · 5 months · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~May 2025 · 2 months · monthly snapshot~May 2025 – ~Jun 2025 · 31 days · monthly snapshot~Jun 2025 – ~Aug 2025 · 2 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – ~Dec 2025 · 30 days · monthly snapshot~Dec 2025 – present · 5 months · monthly snapshot

Change History

35 versions recorded

  1. Dec 2025 — Present [monthly]

    Active Not Recruiting PHASE3

  2. Nov 2025 — Dec 2025 [monthly]

    Active Not Recruiting PHASE3

  3. Sep 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Aug 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Jun 2025 — Aug 2025 [monthly]

    Active Not Recruiting PHASE3

▶ Show 30 earlier versions

  1. May 2025 — Jun 2025 [monthly]

    Active Not Recruiting PHASE3

  2. Mar 2025 — May 2025 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  3. Sep 2024 — Mar 2025 [monthly]

    Recruiting PHASE3

  4. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  5. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE3

  6. May 2024 — Jul 2024 [monthly]

    Recruiting PHASE3

  7. Apr 2024 — May 2024 [monthly]

    Recruiting PHASE3

  8. Nov 2023 — Apr 2024 [monthly]

    Recruiting PHASE3

  9. Sep 2023 — Nov 2023 [monthly]

    Recruiting PHASE3

  10. Feb 2023 — Sep 2023 [monthly]

    Recruiting PHASE3

  11. Nov 2022 — Feb 2023 [monthly]

    Recruiting PHASE3

  12. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE3

  13. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

  14. May 2022 — Jul 2022 [monthly]

    Recruiting PHASE3

  15. Mar 2022 — May 2022 [monthly]

    Recruiting PHASE3

  16. Dec 2021 — Mar 2022 [monthly]

    Recruiting PHASE3

  17. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  18. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

  19. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

  20. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  21. Apr 2021 — Jun 2021 [monthly]

    Recruiting PHASE3

  22. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

  23. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

    Status: Active Not Recruiting → Recruiting

  24. Mar 2019 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  25. Oct 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE3

  26. Jun 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE3

  27. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  28. Sep 2017 — May 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  29. Feb 2017 — Sep 2017 [monthly]

    Recruiting PHASE3

  30. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Jul 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ankara, Turkey (Türkiye) , Barakaldo, Spain , Bari, Italy , Belgrade, Serbia , Belo Horizonte, Brazil , Birmingham, United States , Bochum, Germany , Bordeaux, France , Boston, United States , Bratislava, Slovakia and 59 more locations